Graham D. Thomas

Graham D. Thomas

Auto-generated profile, based on publicly available information

Graham D. Thomas

Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2015 in Science
Verified
Journal Article
Closed access
PDF file
RHRichard N. Hanna
Richard N. Hanna
CCCaglar Cekic
Caglar Cekic
DSDuygu Sag
Duygu Sag
RTRobert Tacke
Robert Tacke
GTGraham D. Thomas
Graham D. Thomas
CHCatherine C. Hedrick
Catherine C. Hedrick
Monocytes block tumor access to the lung: Metastatic cancer is especially hard to treat. In order to find potential new therapeutic targets, scientists are trying to understand the cellular events that promote or prevent metastasis. Hanna et al. now report a role for patrolling monocytes in blocking tumor metastasis to the lungs in mice. Tumors in mice engineered to lack patrolling monocytes showed increased metastasis to the lung but not to other tissues. Patrolling monocytes resided in the microvasculature of the lung, where they engulfed tumor material, which may explain how these cells prevent tumors from colonizing the lung. Science , this issue p. 985

1 June 2015 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
GTGraham Thomas
Graham Thomas
RTRobert Tacke
Robert Tacke
CHCatherine C. Hedrick
Catherine C. Hedrick
RHRichard N. Hanna
Richard N. Hanna
Nonclassical patrolling monocytes are characterized by their unique ability to actively patrol the vascular endothelium under homeostatic and inflammatory conditions. Patrolling monocyte subsets (CX3CR1 high Ly6C − in mouse and CX3CR1 high CD14 dim CD16 + in humans) are distinct from the classical monocyte subsets (CCR2 high Ly6C + in mouse and CCR2 high CD14 + CD16 − in humans) and exhibit unique functions in the vasculature and inflammatory disease. Patrolling monocytes function in several disease settings to remove damaged cells and debris from the vasculature and have been associated with wound healing and the resolution of inflammation in damaged tissues. This review highlights the unique functions of these patrolling monocytes in the vasculature and during inflammation.

7 October 2013 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
SJStephen Jenkins
Stephen Jenkins
DRDominik Ruckerl
Dominik Ruckerl
GTGraham D. Thomas
Graham D. Thomas
JHJames P. Hewitson
James P. Hewitson
SDSheelagh Duncan
Sheelagh Duncan
JAJudith E. Allen
Judith E. Allen
Macrophages (MΦs) colonize tissues during inflammation in two distinct ways: recruitment of monocyte precursors and proliferation of resident cells. We recently revealed a major role for IL-4 in the proliferative expansion of resident MΦs during a Th2-biased tissue nematode infection. We now show that proliferation of MΦs during intestinal as well as tissue nematode infection is restricted to sites of IL-4 production and requires MΦ-intrinsic IL-4R signaling. However, both IL-4Rα–dependent and –independent mechanisms contributed to MΦ proliferation during nematode infections. IL-4R–independent proliferation was controlled by a rise in local CSF-1 levels, but IL-4Rα expression conferred a competitive advantage with higher and more sustained proliferation and increased accumulation of IL-4Rα+ compared with IL-4Rα− cells. Mechanistically, this occurred by conversion of IL-4Rα+ MΦs from a CSF-1–dependent to –independent program of proliferation. Thus, IL-4 increases the relative density of tissue MΦs by overcoming the constraints mediated by the availability of CSF-1. Finally, although both elevated CSF1R and IL-4Rα signaling triggered proliferation above homeostatic levels, only CSF-1 led to the recruitment of monocytes and neutrophils. Thus, the IL-4 pathway of proliferation may have developed as an alternative to CSF-1 to increase resident MΦ numbers without coincident monocyte recruitment.

1 February 2022 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
NBNatalija Budimir
Natalija Budimir
GTGraham D. Thomas
Graham D. Thomas
JDJoseph S. Dolina
Joseph S. Dolina
SSShahram Salek-Ardakani
Shahram Salek-Ardakani
Anti–PD-1/PD-L1 immune checkpoint blockade (ICB) therapy has revolutionized the treatment of many types of cancer over the past decade. The initial therapeutic hypothesis underlying the mechanism of anti–PD-1/PD-L1 ICB was built around the premise that it acts locally in the tumor, reversing the exhaustion of PD-1hiCD8+ T cells by “releasing the brakes.” However, recent studies have provided unprecedented insight into the complexity within the CD8+ T-cell pool in the tumor microenvironment (TME). Single-cell RNA sequencing and epigenetic profiling studies have identified novel cell surface markers, revealing heterogeneity within CD8+ T-cell states classified as unique. Moreover, these studies highlighted that following ICB, CD8+ T-cell states within and outside the TME possess a differential capacity to respond, mobilize to the TME, and seed an effective antitumor immune response. In aggregate, these recent developments have led to a reevaluation of our understanding of both the underlying mechanisms and the sites of action of ICB therapy. Here, we discuss the evidence for the reversibility of CD8+ T-cell exhaustion after ICB treatment and its implication for the further development of cancer immunotherapy.

1 November 2016 in Immunity
Verified
Journal Article
Closed access
GTGraham D. Thomas
Graham D. Thomas
RHRichard N. Hanna
Richard N. Hanna
NVNeelakatan T. Vasudevan
Neelakatan T. Vasudevan
AHAnouk A. Hamers
Anouk A. Hamers
CRCasey E. Romanoski
Casey E. Romanoski
CHCatherine C. Hedrick
Catherine C. Hedrick

1 December 2015 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
ISIftach Shaked
Iftach Shaked
RHRichard N Hanna
Richard N Hanna
HSHelena Shaked
Helena Shaked
GCGrzegorz Chodaczek
Grzegorz Chodaczek
HNHeba N Nowyhed
Heba N Nowyhed
CHCatherine C. Hedrick
Catherine C. Hedrick